The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (29)
June 3, 2002
- Maurer's Healthcare Insight (28)
May 20, 2002
- Maurer's Healthcare Insight (27)
April 29, 2002
- Maurer's Healthcare Insight (27)
April 15, 2002
- Maurer's Healthcare Insight (26)
March 18, 2002
- Maurer's Healthcare Insight (25)
February 25, 2002
- Maurer's Healthcare Insight (20)
September 17, 2001
- Maurer's Healthcare Insight (19)
September 3, 2001
- Maurer's Healthcare Insight(18)
August 6, 2001
- Maurer's Healthcare Insight (17)
July 16, 2001
- Maurer's Healthcare Insight (16)
June 25, 2001
- Maurer's Healthcare Insight (15)
May 21, 2001
- Maurer's Healthcare Insight (14)
April 23, 2001
- Maurer's Healthcare Insight(13)
March 26, 2001
- Maurer's Healthcare Insight(13)
March 26, 2001
- Maurer's Healthcare Insight(13)
March 26, 2001
- Maurer's Healthcare Insight (12)
March 5, 2001
- 2001: A Bridge to the Future
January 1, 2001
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…